LAPORAN AKHIR HASIL PENELITIAN UNGGULAN

Bidang Ilmu : Kesehatan Gizi
dan Makanan
LAPORAN AKHIR HASIL
PENELITIAN UNGGULAN PERGURUAN TINGGIHIBAH BERSAING (TAHUN KE-1)
TAHUN ANGGARAN 2012
Judul
: Studi Mengenai Kadar Homosistein, Asam Folat, Vitamin B6, Vitamin B12,
dan Petanda Kimia Metabolisme Tulang pada Pasien Lupus Eritematosus
Sistemik
Ketua
: dr. Maimun Zulhaidah Arthamin, M. Kes, SpPK
Anggota
: 1. Olivia Anggraeny S.Gz
2. dr.Ermin Rachmawati
Dibiayai oleh Direktorat Jenderal Pendidikan Tinggi, Kementerian Pendidikan dan
Kebudayaan, Melalui DIPA Universitas Brawijaya nomor : 0636/023-04.2.16/15/2012,
tanggal 9 Desember 2011, dan berdasarkan SK Rektor Universitas Brawijaya
Nomor : 058/SK/2012 tanggal 8 Pebruari 2012
Lembaga Penelitian dan Pengabdian kepada Masyarakat
Universitas Brawijaya
2012
ABSTRAK
Artamin, M. Z., Anggraeni, O., Rachmawati, E. 2012. Studi Mengenai Kadar Homosistein,
Asam Folat, Vitamin B6, Vitamin B12, dan Petanda Kimia Metabolisme Tulang
pada Pasien Lupus Eritematosus Sistemik
Lupus eritematosus sistemik (LES) merupakan penyakit autoimun sistemik yang
menyebabkan kerusakan pada beberapa organ. Penelitian yang dilakukan sebelumnya,
melaporkan bahwa angka harapan hidup pasien LES di RSU Dr Saiful Anwar Malang masih
sangat rendah dengan manifestasi klinis yang berat. Salah satu komplikasi LES dengan
kejadian yang cukup tinggi adalah osteoporosis. Osteoporosis pada pasien LES terjadi lebih
dini akibat dari proses inflamasi kronis, obat-obat glukocorticoid, serta faktor metabolik
seperti defisiensi vitamin D dan homosistein. Homosistein merupakan faktor metabolik yang
akhir-akhir ini banyak dipelajari terkait hubungannya dengan beberapa penyakit inflamasi.
Tujuan penelitian ini adalah untuk mengetahui hubungan antara kadar homositein dan
petanda kimia metabolisme tulang pada pasien LES. Penelitian ini merupakan penelitian
analitik observasional dengan pendekatan cross sectional. Sampel penelitian adalah 39
pasien LES dengan kriteria inklusi tertentu, yang diambil sampel darah vena, untuk diperiksa
kadar homosistein, asam folat, B6, B12, CTx, dan Osteocalcin serum. Pemeriksaan kadar
variabel tersebut dilakukan dengan ELISA Kit spesifik. Hasil penelitian menunjukkan bahwa
71,8% kadar homositein pada sampel pasien LES mengalami peningkatan (>10 μmol/L).
Peningkatan kadar homositein ini berhubungan dengan peningkatan kadar CTx (p=0,000,
R=0,943) serta penurunan kadar Osteocalcin (p=0,000, R= 0,771). Selain itu, diperoleh data
bahwa kadar asam folat, vitamin B6, dan vitamin B12 cenderung rendah. Hal ini disebabkan
proses inflamasi dan proses peningkatan turn over ketiga kofaktor metabolisme homosistein
tersebut sehingga terjadi kondisi hiperhomositeinemia, dimana kondisi ini akan
mempengaruhi proses metabolisme tulang.
Kata kunci : LES, homositein, Asam Folat, B6, B12, CTx, Osteocalcin, Osteoporosis
ABSTRACT
Artamin, M. Z., Anggraeni, O., Rachmawati, E. 2012. Study of Serum Homocysteine, Folic
Acid, Vitamin B6, B12, and Biochemical Parameters of Bone Metabolism in Patients
with Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes
multiple organ damage. Previous research reported that life expectancy of patients with SLE
in RSU Dr. Saiful Anwar Malang is still very low with severe clinical manifestations. One of
SLE complication with high incidence was osteoporosis. Osteoporosis in SLE patients occur
earlier due to a chronic inflammatory process, glukocorticoid drugs and metabolic factors
such as vitamin D deficiency and homocysteine. Homocysteine is a metabolic factor lately
been studied related with several inflammatory diseases. The purpose of this study was to
determine the relationship between homositein levels and biochemical parameters of bone
metabolism in patients with SLE. This study was observational analytic with cross sectional
approach. The research sample was 39 SLE patients with specific inclusion criteria, a
venous blood sample was taken to be examined levels of serum homocysteine, folic acid,
B6, B12, CTx, and osteocalcin by specific ELISA kit. The results showed that 71.8%
homositein levels in patient samples SLE was increased (> 10 μmol/L). Elevated levels of
homositein associated with elevated levels of CTx (p = 0.000, R = 0.943) and decreased
levels of osteocalcin (p = 0.000, R = 0.771). In addition, the data showed that the levels of
folic acid, vitamin B6, and vitamin B12 tend to be low. This is due to chronic inflammatory
process and the increase in cell turn over, so the three cofactors of homocysteine
metabolism will decrease, and resulting hyperhomocyssteinemia conditions, which affect on
bone metabolism.
Key word : SLE, homocysteine, Folic Acid, B6, B12, CTx, Osteocalcin, Osteoporosis
RINGKASAN
Judul: Studi Mengenai Kadar Homosistein, Asam Folat, Vitamin B6, Vitamin B12, dan
Petanda Kimia Metabolisme Tulang pada Pasien Lupus Eritematosus Sistemik
Latar Belakang:
Lupus eritematosus sistemik (LES) merupakan penyakit autoimun sistemik yang
menyebabkan kerusakan pada beberapa organ dengan prevalensi yang cukup tinggi.
Penelitian yang dilakukan sebelumnya, melaporkan bahwa angka harapan hidup pasien
LES di RSU Dr Saiful Anwar Malang masih sangat rendah dengan manifestasi klinis yang
berat. Tingginya angka morbiditas dan mortalitas pasien LES ini diakibatkan oleh perjalanan
penyakit itu sendiri maupun akibat komplikasi. Salah satu komplikasi LES dengan kejadian
yang cukup tinggi adalah osteoporosis. Osteoporosis pada pasien LES terjadi lebih dini
akibat dari proses inflamasi kronis, obat-obat glukocorticoid, serta faktor metabolik seperti
defisiensi vitamin D dan homosistein. Homosistein merupakan faktor metabolik yang akhirakhir ini banyak dipelajari terkait hubungannya dengan beberapa penyakit inflamasi. Tujuan
penelitian ini adalah untuk mengetahui hubungan antara kadar homositein dan petanda
kimia metabolisme tulang pada pasien LES.
Metode Penelitian:
Penelitian ini merupakan penelitian analitik observasional dengan pendekatan cross
sectional. Sampel penelitian adalah pasien LES di poli reumatologi dan bangsal rawat inap
RSU dr. Saiful Anwar Malang, dengan kriteria inklusi: wanita, usia 18-43 tahun, durasi
penyakit 6 bulan – 2 tahun sejak pertama kali didiagnosis, tidak sedang hamil atau
menyusui, batasan konsumsi steroid (Methylprednisolone < 30 mg/hari), tidak sedang
menggunakan terapi hormon pengganti, suplemen asam folat, dan vitamin B, atau obatobatan seperti methotrexate, anti convulsan, nitrous oxide, theophylline. Jumlah sampel
minimal yang diperoleh berdasarkan hasil penghitungan adalah 37 pasien. Selanjutnya
pasien yang bersedia dan menandatangani informed consent diambil darah vena sebanyak
5 cc, untuk selanjutnya diukur kadar homositein, asam folat, B6, B12, CTx, dan osteocalcin.
Pengukuran variabel tersebut dilakukan dengan metode ELISA dengan menggunakan
ELISA Kit spesifik. Selain itu, pasien juga diminta untuk mengisi qestionaire intake makanan
sehari-hari untuk mengetahui jumlah intake dari asam folat, B6, dan B12 pasien.
Hasil Penelitian:
Hasil penelitian menunjukkan bahwa 71,8% kadar homositein pada sampel pasien LES
meningkat (>10 μmol/L). Peningkatan kadar homositein ini berhubungan dengan
peningkatan kadar CTx (p=0,000, R=0,943) serta penurunan kadar Osteocalcin (p=0,000,
R= 0,771). Selain itu, diperoleh data bahwa kadar asam folat pada 56,4% sampel
mengalami penurunan (<5,4 nmol/L), kadar vitamin B6 pada 46,2% sampel menurun (< 6
nmol/L), begitu juga kadar vitamin B12 pada 51,3% dari sampel juga didapatkan mengalami
penurunan (<150 pmol/L). Hal ini diduga disebabkan karena inflamasi kronis akibat proses
autoimun serta peningkatan turn over sel pada pasien LES. Ketiga zat tersebut merupakan
kofaktor metabolisme homosistein, sehingga apabila kadar nya rendah di dalam tubuh,
maka akan terjadi kondisi hiperhomositeinemia, yang selanjutnya dapat mempengaruhi
proses metabolisme tulang.
Kesimpulan :
Dari hasil penelitian ini dapat disimpulkan bahwa pada pasien LES cenderung mengalami
peningkatan kadar homositen. Peningkatan kadar homosistein ini berpengaruh terhadap
aktivitas metabolisme tulang, yaitu peningkatan proses resorbsi tulang yang ditandai dengan
peningkatan kadar CTx dan penurunan kadar OC serum. Ketidakseimbangan metabolisme
tulang ini dalam jangka waktu tertentu akan menyebabkan penurunan densitas masa tulang
yang akan bermanifestasi sebagai osteoporosis. Penyebab peningkatan kadar homositein
ini adalah penurunan kadar asam folat, B6, dan B12, yang diduga akibat proses inflamasi
yang terjadi pada pasien LES. Dari data hasil penelitan ini, diharapkan dapat dijadikan data
dasar untuk penelitian lebih lanjut mengenai homositein dan osteoporosis yang mungkin ke
depan nya dapat dipertimbangkan mengenai pemberian terapi adjuvant asam folat, B6, dan
B12 pada pasien LES untuk mencegah terjadinya proses osteoporosis dini.
SUMMARY
Title: Study of Serum Homocysteine, Folic Acid, Vitamin B6, B12, and Biochemical
Parameters of Bone Metabolism in Patients with Systemic Lupus Erythematosus
Background:
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes multiple organ
damage. Previous research reported that life expectancy of SLE patients in RSU Dr. Saiful
Anwar Malang is still very low with severe clinical manifestations. The high rates of morbidity
and mortality in patients SLE is caused by the disease course itself and the complications.
One of the SLE complication with high incidence was osteoporosis. Osteoporosis occur
earlier in patient with SLE, it causes by chronic inflammatory process, glukocorticoid drugs,
and metabolic factors such as vitamin D deficiency and homocysteine. Homocysteine is a
metabolic factor lately been studied related to do with several inflammatory diseases. The
purpose of this study was to determine the relationship between levels homositein and
biochemical parameter of bone metabolism in patients with SLE.
Methods:
This study was observational analytic with cross sectional approach. The research sample
was patient diagnosed as SLE at poly rheumatology and at ward RSU dr. Saiful Anwar
Malang. Inclussion criteria: women, aged 18-43 years, disease duration 6 months - 2 years
since first diagnosed, not pregnant or breastfeeding, limit consumption of steroids
(Methylprednisolone <30 mg / day), not using hormone replacement therapy, folic acid or
vitamin B supplements, and drugs such as methotrexate, anticonvulsant, nitrous oxide,
theophylline. Minimum number of samples obtained by the results of the calculation are 37
patients. Furthermore, patients who are willing and informed consent, was taken 5 cc venous
blood to measured homositein, folic acid, B6, B12, CTx, and osteocalcins serum level.
Measurement of these variables is done by ELISA method using a specific ELISA kit. In
addition, patients were also asked to fill qestionaire daily food intake to determine the
amount of intake of folic acid, B6, and B12.
Results:
The results showed that 71.8% of patient samples have increase of homositein level (> 10
μmol / L). Elevation levels of homositein associated with elevated levels of CTx (p = 0.000, R
= 0.943) and decreased levels of Osteocalcin (p = 0.000, R = 0.771). In addition, the data
showed that the levels of folic acid in the was decreased (<5.4 nmol / L) at 56.4% sample,
decreasing vitamin B6 level (<6 nmol / L) at 46.2% of sampel, as well as levels of vitamin
B12 in 51.3% of samples were also found to decline (<150 pmol / L). This is thought to be
caused by chronic inflammation caused by an autoimmune process and increase cell
turnover in patients with SLE. These three substances are important cofactors of
homocysteine metabolism, so if its low levels in the body, it will cause hiperhomositeinemia
conditions, which in turn can affect bone metabolism.
Conclusion:
From these results it can be concluded that the patients tend to have elevated levels of LES
homositen. Elevated levels of homocysteine associated with bone metabolic activities
(increased levels of CTx and decreased levels of serum OC). This imbalance of bone
metabolism in a certain period of time will cause a loss of bone density that will manifest as
osteoporosis. The cause of elevated levels homositein are decreased levels of folic acid, B6,
and B12, which may be due to the inflammatory process that occurs in patients with LES.
From the research outcome data, is expected to be used as a baseline for further studies on
homositein and osteoporosis that may be considered forward for the adjuvant therapy of folic
acid, B6, and B12 in patients with LES to prevent the premature osteoporosis.
DAFTAR PUSTAKA
Baines M., Kredan, J. Usher, A. Davison, G. Higgins, W. Taylor, C. West, W.D. Fraser, L.R.
Ranganath. 2007. The association of homocysteine and its determinants MTHFR
genotype, folate, vitamin B12 and vitamin B6 with bone mineral density in
postmenopausal British women. Bone, vol. 40, page 730–736
Bezerra M.C., J.F. Carvalho, A.S. Prokopowitsch, dan R.M.R. Pereira. 2005. RANK, RANKL
and osteoprotegerin in arthritic bone loss. Brazilian Journal of Medical and Biological
Research, vol. 38, page 161-170
Bultink I. E. M. 2012. Osteoporosis and Fractures in Systemic Lupus Erythematosus.
Arthritis Care & Research, vol. 64, no. 1, page 2–8
Cagnacci A., Cannoletta M., Baldassari F, dan Volpe A. 2004. Low Vitamin B12 and Bone
Loss: A Role for Folate Deficiency. J Clin Endocrinol Metab 89(9):4768–4774
Chigurupati S., Zelan Wei, Cherine Belal, Myriam Vandermey, George Kyriazis, Thiruma
Arumugam, Sic L. Chan. 2009. The Homocysteine-Inducible Endoplasmic Reticulum
Stress Protein Counteracts Calcium Store Depletion and Induction of C/EBP
Homologous Protein in aA Neurotoxin Model of Parkinson Disease. JBC Papers in
Press, vol. 5
Cooper C. 2003. Epidemiology of osteoporosis. In Primer on the Metabolic Bone Disease
and Disorders of Mineral Metabolism 307–313 edn 5 (Ed Favus M). Washington DC:
American Society for Bone and Mineral Research
Elshorbagy A. K., Clara Gram Gjesdal, Eha Nurk, Grethe S. Tell, Per M. Ueland, Ottar
Nyard, Aage Tverdal, Stein E. Vollset, A. David Smith, Helga Refsum. 2009.
Cysteine, homocysteine and bone mineral density: A role for body composition.
Bone, vol. 44, page 954–958
Gjesdal C. G., Stein Emil Vollset, Per Magne Ueland, Helga Refsum, Christian A. Drevon,
Hakon K. Gjessing, Grethe S. Tell. 2006. Plasma Total Homocysteine Level and
Bone Mineral Density. ARCH INTERN MED, vol 166, no. 9, page 88-95
Gordon C. Long-term complications of systemic lupus erythematosus. Rheumatology, vol. 4,
page 1095–1100
Herrmann M., Johannes Schmidt , Natascha Umanskaya, Graziana Colaianni, Fuad Al
Marrawi , Thomas Widmann, Alberta Zallone, Britt Wildemann, Wolfgang Herrmann.
2007. Stimulation of osteoclast activity by low B-vitamin concentrations. Bone, vol.
41, page 584–591
Herrmann M., Thomas Widmann, Graziana Colaianni, Silvia Colucci, Alberta Zallone, dan
Wolfgang Herrmann. 2005. Increased Osteoclast Activity in the Presence of
Increased Homocysteine Concentrations. Clinical Chemistry, vol. 5, no. 12, page
2348–2353
Keith R. 2007. Osteoporosis: Integrating Biomarkers and Other Diagnostic Correlates into
the Management of Bone Fragility. Alternative Medicine Review, vol. 12, no. 2, page
113- 145
Kawiyana IKS. 2009. Osteoporosis : Patogenesis, Diagnosis Dan Penanganan Terkini. J
Peny Dalam;10(2):157-168
Kim D.J., Park BL, Koh JM, Kim GS,Kim LH, Cheong HS, Shin HD,Hong JM,Kim TH, Shin
HI,Park EK, and Kim SY. 2006. Methionine synthase reductase polymorphisms are
associated with serum osteocalcin levels in postmenopausal women. Exp Mol Med.
38(5):519-24.
Koh J.,Young-Sun Lee, Yang Soon Kim, Duk Jae Kim, Hong-Hee Kim, Joong-Yeol Park, KiUp Lee, dan Ghi Su Kim. 2006. Homocysteine Enhances Bone Resorption by
Stimulation of Osteoclast Formation and Activity Through Increased Intracellular ROS
Generation. Journal of Bone and Mineral Research, vol. 21, no. 7, page 1003-1011
Krishnamurthy S. dan Mahadevan S. 2011. Systemic Lupus Erythematosus: Recent
Concepts in Genomics, Pathogenetic Mechanisms, and Therapies. International
Scholarly Research Network (ISRN) Immunology, vol. 2011, page 1-7
Lacativa P. G. dan Farias M. L. 2010. Osteoporosis and Inflammation. Arq Bras Endocrinol
Metab, vol. 54, no. 2, page 123-133
Lane N. E. 2006. Therapy Insight: osteoporosis and osteonecrosis in systemic lupus
erythematosus. NATURE CLINICAL PRACTICE RHEUMATOLOGY, vol. 2, no. 10,
page 562-569
Levasseur R. 2009. Bone tissue and hyperhomocysteinemia. Joint Bone Spine, vol. 76,
page 234-240
Mattson M. P. dan Shea Thomas B. 2003. Folate and homocysteine metabolism in neural
plasticity and neurodegenerative disorders. Trends in Neuroscience, vol. 26, issue 3,
pages 137–146
Mok C C, Lau C S. 2003. Pathogenesis of systemic lupus erythematosus. J Clin Pathol, vol.
56, page 481–490
Okabe R, Nakatsuka K, Inaba M, et al. Clinical Evaluation of the Elecsys β-CrossLaps
Serum Assay, a New Assay for Degradation Product of Type I Collagen CTelopeptides. Clinical Chemistry 2001;47(8):1410-1414.
Park S. J., Kim K. J., Kim W. U., Oh I. H., Cho C. S. 2012. Involvement of endoplasmic
reticulum stress in homocysteine-induced apoptosis of osteoblastic cells. Journal of
Bone and Mineral Metabolism, vol. 6
Prado, D, Guerra-Shinohara,Galdieri, Terreri, Hilário MO. 2006. Increased concentration of
plasma homocysteine in children with systemic lupus erythematosus. Clinical and
Experimental Rheumatology; 24: 594-598.
Raisz L. J. 2005. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. The
Journal of Clinical Investigation, vol. 115, page 3318–3325
Seibel M. J. 2005. Biochemical Markers of Bone Turnover Part I : Biochemistry and
Variability. Clinical Biochemist Review, vol. 26, page 97-121
Selhub J. 2007. Homocysteine Metabolism. Annual Review of Nutrition, vol. 19, page 217–
246
Schroecksnadel K, Frick B, Winkler C, Leblhuber F, Wirleitner B dan Fuchs D. 2003.
Review : Hyperhomocysteinemia and Immune Activation. Clin Chem Lab Med;
41(11):1438–1443
Singer F. R. dan Eyre D. R. 2008. Using biochemical markers of bone turnover in clinical
practice. Clincal Joirnal of Medicine, vol. 75, no. 10, page 739-756
Wu J. T. 2007. Circulating Homocysteine Is An Inflammation Marker And A Risk Factor of
Life-Threatening Inflammatory Diseases. Journal of Biomedical & Laboratory
Sciences, vol. 19, no. 4, page 107-11